Kristin Palmsten

Kristin Palmsten

Auto-generated profile, based on publicly available information

Kristin Palmsten

Pregnancy and Child Health Research Center HealthPartners Institute Minneapolis Minnesota USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2019 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Closed access
PDF file
GBGretchen Bandoli
Gretchen Bandoli
KPKristin Palmsten
Kristin Palmsten
CCChristina D Chambers
Christina D Chambers

1 June 2020 in Rheumatology
Verified
Journal Article
Open access
PDF file
KPKristin Palmsten
Kristin Palmsten
GBGretchen Bandoli
Gretchen Bandoli
GVGabriela Vazquez-Benitez
Gabriela Vazquez-Benitez
MXMin Xi
Min Xi
DJDiana L Johnson
Diana L Johnson
CCChristina D Chambers
Christina D Chambers
To evaluate the associations between oral corticosteroid (OCS) dose early and late in pregnancy and preterm birth (PTB) among women with RA. Pregnant women in the MotherToBaby Pregnancy Studies (2003–2014) with RA (n = 528) were included in the primary analysis. Information was collected by phone interview and from medical records. We estimated risk ratios (RR) for OCS dose trajectories and other disease-related medications before gestational day 140 and hazard ratios (HR) for time-varying exposures after gestational day 139. PTB risk was 15.5% overall. Compared with no OCS, PTB risk was increased in high (adjusted (a)RR: 4.77 (95% CI: 2.76, 8.26)) and medium (aRR: 1.81 (95% CI: 1.10, 2.97)) cumulative OCS dose trajectories during the first 139 gestational days. The low cumulative trajectory group was associated with an increased risk of PTB that was not statistically significant (aRR: 1.38 (95% CI: 0.79, 2.38)), and DMARDs were not associated with PTB (biologic DMARDs aHR: 1.08 (95% CI: 0.70, 1.66); non-biologic DMARDs aHR: 0.87 (95% CI: 0.55, 1.38)). OCS exposure to ⩾10 mg of prednisone equivalent daily dose after gestational day 139 vs none was associated with increased PTB rate (aHR: 2.45 (95% CI: 1.32, 4.56)), whereas <10 mg was associated with a modestly increased rate of PTB that was not statistically significant (aHR: 1.18 (95% CI: 0.60, 2.30)). Higher OCS doses vs no OCS use, both earlier and later in pregnancy, were associated with an increase in PTB among women with RA.

28 February 2018 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
KPKristin Palmsten
Kristin Palmsten
MRMatthieu Rolland
Matthieu Rolland
MHMary F. Hebert
Mary F. Hebert
MCMegan E.B. Clowse
Megan E.B. Clowse
MSMichael Schatz
Michael Schatz
CCChristina D Chambers
Christina D Chambers

21 May 2018 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Closed access
PDF file
GBGretchen Bandoli
Gretchen Bandoli
KPKristin Palmsten
Kristin Palmsten
CCChristina D Chambers
Christina D Chambers
LJLaura L. Jelliffe‐Pawlowski
Laura L. Jelliffe‐Pawlowski
RBRebecca J. Baer
Rebecca J. Baer
CTCaroline A. Thompson
Caroline A. Thompson

1 July 2018 in Placenta
Verified
Journal Article
Closed access
KPKristin Palmsten
Kristin Palmsten
KNKatharine K. Nelson
Katharine K. Nelson
LLLouise C. Laurent
Louise C. Laurent
SPSoojin Park
Soojin Park
CCChristina D Chambers
Christina D Chambers
MPMana Parast
Mana Parast

11 August 2020 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
KPKristin Palmsten
Kristin Palmsten
GBGretchen Bandoli
Gretchen Bandoli
JWJim Watkins
Jim Watkins
GVGabriela Vazquez-Benitez
Gabriela Vazquez-Benitez
TGTodd P. Gilmer
Todd P. Gilmer
CCChristina D Chambers
Christina D Chambers